CorMedix Inc (CRMD) vs Monopar Therapeutics Inc. (MNPR)

CorMedix Inc and Monopar Therapeutics Inc. are both Biotechnology companies. CorMedix Inc and Monopar Therapeutics Inc. are of similar size ($608.0M and $602.8M). Monopar Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 3.3×. CorMedix Inc has the higher net margin (40.5% vs 0.00%) and the higher return on invested capital (38.8% vs 0.00%). Across the 13 metrics below, CorMedix Inc leads on 11 and Monopar Therapeutics Inc. on 2.

Valuation

Metric CRMD MNPR Biotechnology median
P/E 3.26 n/m 7.88
P/S 1.33 n/m 11.47
P/B 1.34 5.56 2.52
Price to free cash flow 2.46 n/m 21.16
EV/EBITDA 1.99 n/m 0.74
EV/Sales 1.09 n/m 10.73
Earnings yield 30.70% (2.55%) (28.84%)
Free cash flow yield 40.67% (1.67%) (23.03%)

Profitability

Metric CRMD MNPR Biotechnology median
Gross margin 82.78% — 65.16%
Operating margin 46.95% 0.00% 0.00%
Net margin 40.49% 0.00% 0.00%
Free cash flow margin 54.17% 0.00% 0.00%
Return on equity 54.93% (19.50%) (57.72%)
Return on assets 32.36% (18.90%) (49.22%)
Return on invested capital 38.84% 0.00% 0.00%

Growth

Metric CRMD MNPR Biotechnology median
Revenue growth (TTM) 280.50% — 5.64%
EPS growth (last fiscal year) 780.00% 54.99% —
Revenue growth, 5-year CAGR 305.79% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRMD MNPR Biotechnology median
Debt to equity 0.32 0.00 0.00
Current ratio 2.56 33.56 4.73
Net debt to EBITDA (0.02) 8.06 0.96

Dividend

Metric CRMD MNPR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRMD MNPR Biotechnology median
Market cap 607.97m 602.75m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack